HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Naomi M Seki Selected Research

S-268019-b COVID-19 vaccine

1/2022Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Naomi M Seki Research Topics

Disease

1COVID-19
01/2022
1Weight Loss (Weight Reduction)
01/2022

Drug/Important Bio-Agent (IBA)

2VaccinesIBA
01/2022 - 01/2022
1S-268019-b COVID-19 vaccineIBA
01/2022
1BNT162 VaccineIBA
01/2022
1Proteins (Proteins, Gene)FDA Link
01/2022